Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Supplement Health Claim Regs Public Meeting Slated For Early 2000

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

FDA plans to hold a public meeting in the first quarter of 2000 to discuss possible ways to amend its general health claims regulations for dietary supplements, the agency announced in a Dec. 1 Federal Register notice.

You may also be interested in...



Supplement Health Claims "Intermediate Category" Created By CFSAN

Dietary supplement manufacturers will be able to market products with health claims supported by indefinite scientific evidence under an interim procedure set forth in the Oct. 6 Federal Register.

Supplement Health Claims "Intermediate Category" Created By CFSAN

Dietary supplement manufacturers will be able to market products with health claims supported by indefinite scientific evidence under an interim procedure set forth in the Oct. 6 Federal Register.

Supplement Health Claims "Intermediate Category" Created By CFSAN

Dietary supplement manufacturers will be able to market products with health claims supported by indefinite scientific evidence under an interim procedure set forth in the Oct. 6 Federal Register.

Table

View full table

Related Content

HBW Insight
Pink Sheet
HBW Insight
Pink Sheet

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages

Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug

See All
UsernamePublicRestriction

Register

PS090655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By